The Court has ruled that the asserted claims of US patents 7,410,978 , 7,759,359, 7,781,448, 7,781,449 and 7,763,635 for Sanctura XR are invalid.
Sanctura XR is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.
The company’s abbreviated new drug application for a generic Sanctura XR is pending with the FDA.
Sanctura XR had total US sales of approximately $68m for the twelve months ending February 29, 2012, according to IMS Health data.